We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Akero Therapeutics (AKRO) Run Higher on Strong Earnings Estimate Revisions?
Read MoreHide Full Article
Akero Therapeutics, Inc. (AKRO - Free Report) is a clinical-stage cardio-metabolic company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AKRO earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Valecould be a solid choice for investors.
Current Quarter Estimates for AKRO
In the past 60 days, three estimates have gone higher for Akero Therapeutics while none has gone lower in the same time period. The trend has been pretty favorable too, with estimates moving from a loss of $1.09 per share 60 days ago, to a loss of 72 cents per share today, a move of 34%.
Current Year Estimates for AKRO
Meanwhile, Akero Therapeutics’ current year figures are also looking quite promising, with three estimates moving higher in the past two months, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, moving from a loss of $4.50 per share 60 days ago to a loss of $2.97 per share today, a move of 34%.
The stock has also started to move higher lately, adding 6.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Image: Bigstock
Can Akero Therapeutics (AKRO) Run Higher on Strong Earnings Estimate Revisions?
Akero Therapeutics, Inc. (AKRO - Free Report) is a clinical-stage cardio-metabolic company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AKRO earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Valecould be a solid choice for investors.
Current Quarter Estimates for AKRO
In the past 60 days, three estimates have gone higher for Akero Therapeutics while none has gone lower in the same time period. The trend has been pretty favorable too, with estimates moving from a loss of $1.09 per share 60 days ago, to a loss of 72 cents per share today, a move of 34%.
Current Year Estimates for AKRO
Meanwhile, Akero Therapeutics’ current year figures are also looking quite promising, with three estimates moving higher in the past two months, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, moving from a loss of $4.50 per share 60 days ago to a loss of $2.97 per share today, a move of 34%.
Akero Therapeutics, Inc. Price and Consensus
Akero Therapeutics, Inc. price-consensus-chart | Akero Therapeutics, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 6.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>